Friday 6 November 2026
Export STE’s income statement to Excel — free account
STERIS plc
STE Healthcare Medical Devices
STERIS plc’s revenue for fiscal 2026 (year ended March 2026) was $5.9 billion, up 8.73% from fiscal 2025.
- Revenue
- +8.79%
- EPS
- +12.8%
- Free cash flow
- +43.6%
- Total debt
- −0.21%
Quarter to September 2026, against a year earlier
252.70
1.42
−0.56%
Follow STE
Alert me
| Sep '26 From the 10-Q filed 5 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
24.82 | 25.65 | 27.78 | 35.26 |
+8 more quarters Free account |
P/S ratio |
3.31 | 3.40 | 3.66 | 4.27 | |
P/FCF ratio |
21.80 | 21.96 | 22.09 | 26.58 | |
P/Operating CF |
70.71 | 55.98 | 64.74 | 83.49 | |
P/B ratio |
2.81 | 2.85 | 3.02 | 3.47 | |
Price to Tangible BV |
12.80 | 14.00 | 15.71 | 20.01 | |
EV/Sales |
3.54 | 3.64 | 3.91 | 4.55 | |
EV/EBITDA |
13.09 | 13.45 | 14.61 | 17.82 | |
EV/Operating CF |
16.90 | 17.05 | 17.30 | 20.92 | |
EV/FCF |
23.26 | 23.46 | 23.61 | 28.29 | |
Quick Ratio |
1.27 | 1.17 | 1.34 | 1.53 | |
Current Ratio |
2.05 | 1.91 | 2.09 | 2.48 | |
Net Debt/EBITDA |
3.24 | 3.44 | 3.39 | 3.73 | |
Debt/Assets |
17.67% | 17.64% | 17.99% | 17.92% | |
Debt/Equity |
0.26 | 0.26 | 0.27 | 0.26 | |
Asset Turnover |
0.58 | 0.57 | 0.57 | 0.57 | |
Operating CF/Net income |
1.35 | 1.83 | 1.52 | 1.55 | |
Capex/Depreciation |
0.00 | (0.71) | (0.73) | (0.72) | |
Interest Coverage |
— | 18.09 | 21.11 | 18.34 | |
Research and Development Expense of Revenue |
0.00% | 1.92% | 1.81% | 1.97% | |
Selling, General and Administrative Expense of Revenue |
23.04% | 24.77% | 22.16% | 23.55% | |
Intangible Assets out of Total Assets |
0.53 | 0.54 | 0.54 | 0.56 | |
Share Based Compensation of Revenue |
1.37% | 0.86% | 0.81% | 1.05% | |
Graham Net Nets |
(0.05) | (0.05) | (0.05) | (0.05) | |
Graham Number |
119.27 | 116.91 | 114.57 | 108.67 | |
Earnings Yield |
4.03% | 3.90% | 3.60% | 2.84% | |
Free Cash Flow Yield |
4.59% | 4.55% | 4.53% | 3.76% | |
Revenue per Share |
16.33 | 15.29 | 16.17 | 15.24 | |
Operating CF per Share |
2.97 | 3.76 | 3.42 | 3.04 | |
Capex per Share |
0.00 | (0.90) | (0.92) | (0.90) | |
Free Cash Flow per Share |
2.97 | 2.86 | 2.50 | 2.14 | |
Cash per Share |
5.46 | 4.94 | 4.48 | 4.31 | |
Shareholders Equity per Share |
74.73 | 73.99 | 73.29 | 72.99 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
74.73 | 73.99 | 73.29 | 72.99 | |
Free Cash Flow |
289.00 | 279.60 | 245.30 | 209.90 | |
Working Capital |
1,271.40 | 1,162.50 | 1,249.60 | 1,363.90 | |
Capital Expenditures |
— | (87.50) | (90.10) | (88.30) | |
Net Current Asset Value |
(962.70) | (1,069.00) | (1,145.40) | (1,137.30) | |
EV/EBIT |
18.63 | 19.24 | 21.06 | 26.46 | |
Capex to Sales |
0.00 | 0.06 | 0.06 | 0.06 | |
Price to Operating Income |
17.46 | 18.00 | 19.71 | 24.87 | |
| Other line items | |||||
Average Receivables |
976.25 | 980.15 | 1,068.40 | 952.90 | |
Average Payables |
321.55 | 322.50 | 309.80 | 261.70 | |
Average Inventory |
697.75 | 676.65 | 606.55 | 661.53 | |
Average Assets |
10,562.15 | 10,570.55 | 10,442.00 | 10,299.88 | |
Average Common Equity |
7,147.10 | 7,095.55 | 6,906.55 | 6,798.22 |
Columns are period end dates · fundamentals updated 5 Nov 2026